PDLIM7 and diffuse large B-cell lymphoma: According to Crombie and LaCasce (2019), LMP1 is expressed in approximately two-thirds of DLBCL patients corresponding to latency phase II, while the rest are characterized by EBNA2 expression, which denotes latency type III [6].